Subscribe for Free (RSS + E-mail)

RSS + E-mail

Boston Angel Investors →
Featured▾
- Boston Angel Investors →
Xconomy National
Xperience
Tech + Life▾
- View More in Xperience ›
Our
Cities▾
Tech
Channels ▾
Meet the
Xconomists ▾
Our
Events ▾

ltimmerman

Luke Timmerman

Luke is an award-winning journalist specializing in life sciences. Before joining Xconomy, he was the U.S. biotechnology reporter for Bloomberg News, based in San Francisco. There, he led coverage of major medical meetings and broke news about the industry’s top companies. His stories appeared in The New York Times, Los Angeles Times, Boston Globe, and International Herald Tribune. Before that, his passionate coverage of biotechnology won many awards for The Seattle Times.

While at the Times, Luke was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award, the Sigma Delta Chi prize from the Society of Professional Journalists, the Society of American Business Editors and Writers award, an honorable mention Gerald Loeb Award, and was nominated for the Pulitzer Prize in public service. At Xconomy, he was honored in 2012 as a finalist for the Gerald Loeb Award, and received a SABEW award for biotech columns.

Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison. In 2005-2006, he was a Knight Science Journalism Fellow at MIT. In his spare time, Luke enjoys running, mountaineering, and fantasy baseball. Having grown up in Wisconsin, he is, naturally, a lifelong fan of the Green Bay Packers and the Wisconsin Badgers.

Recent posts

Profiles in Long-Termism: Sarepta Therapeutics CEO Chris Garabedian

Biotech is a long-term business, in a world that places more value on short-term thinking. Pharma companies often cut long-term R&D budgets, or do disastrous mega-mergers, mainly to juice their... Read more »
UW Spinout Cardiac Insight Wins FDA OK for Heartbeat Monitor

[Updated: 3:55 pm PT] Medical device startups often need to live on shoestring budgets as a lot of venture capital has dried up in the wake of the Great... Read more »
Cellana Cuts Algae Biofuel Deal with Finland Oil Giant

Algae biofuel was hot, then cold. Now it looks to be warming up again—kinda, sorta, maybe.

San Diego-based Cellana is the latest example of an aspiring algae biofuel company that has... Read more »
CytomX Snags $25M From Pfizer to Make Souped-Up Antibodies

Pfizer was tripped up a couple years ago, when safety concerns emerged around the first drug ever approved that could combine the targeting ability of an antibody with a toxin to... Read more »
Mobisante Grabs $4.2M for Mobile Ultrasound Tools

[Updated 5:42 pm PT] Redmond, WA-based Mobisante has pulled in some new cash to support its dream of making ultrasound technology available on low-cost, lightweight smartphones and tablets.

Mobisante... Read more »
Second Genome Gets J&J Deal, $6.5M, to Explore Bugs of the Gut

Scientists have been blown away by things they’ve learned the past couple years about the trillions of bacterial friends and enemies that we human beings live with every day. Now we’re... Read more »
ASCO Wrap-Up: Cancer News from the East, South, & Rockies

The herds who attended the American Society of Clinical Oncology have now gone home after a frenzied few days of absorbing what’s new in cancer R&D. Yesterday, I wrapped up some... Read more »
Protagonist Pulls in $14M, Led by J&J, For Peptide Pills

Not many companies know how to make peptide molecules that can be packaged in a pill, but Menlo Park, CA-based Protagonist Therapeutics just got a vote of confidence that it can... Read more »
ASCO Wrap-Up: Cancer News from the West Coast

Anybody with a more than passing interest in cancer has been transfixed the last few days by the news coming out of Chicago. The American Society of Clinical Oncology (ASCO) annual... Read more »
The Biotech IPO Scorecard: Who’s Up, Who’s Down in 2013

Remember Plexxikon? The Berkeley, CA-based company had a lot of talent for structural biology-based drug design, an impressive new treatment for melanoma, and a strong management team.

Two years ago, nobody... Read more »
Merck Joins Bristol, Genentech in Great Cancer Immunotherapy Race

Merck wasn’t the first company to develop targeted antibody drugs 15 years ago, and wasn’t first to show immunotherapy could work against cancer a couple years ago. But the giant drugmaker... Read more »
Plexxikon Leadership Duo, Peter Hirth and Kathy Glaub, Exit Daiichi

Peter Hirth and Kathy Glaub, the executive duo who led Berkeley, CA-based Plexxikon on its quest to develop an important new treatment for melanoma, worked together for more than a decade,... Read more »
Oncothyreon Nabs $10M, Pays $10M, For Array Biopharma Cancer Drug

[Updated: 6:35 am PT 5/31] Seattle-based Oncothyreon disappointed a lot of people last year who were betting that it had found a promising new immunotherapy for patients with lung... Read more »
Cadence Biomedical Nets $1M, Loads of Press, for Walk-Assist Device

Brian Glaister has had the kind of run over the past few weeks that entrepreneurs dream of.

After years of toiling in obscurity, working just to develop a decent prototype, his... Read more »
Mirador Biomedical Study: Spend $35 on Our Device & Save $116

Seattle-based Mirador Biomedical is trying to sell hospitals a little digital device for about $35 apiece, in hopes of preventing a rare and disastrous thing from happening to patients. Now the... Read more »
Ekos, Maker of Ultrasound Blood Clot Dissolver, Bought for $180M

Ekos has been around a long time in the business of making ultrasound devices to improve the treatment of cardiovascular disease. Now it’s getting some rewards for that investment of time... Read more »
Cardeas Pharma Snags $34M For Antibiotic Against Hospital Infections

Seattle-based Cardeas Pharma just raised a lot more cash to fight a big problem that hospitals wrestle with every day, and which they’d rather not say much about publicly.

Cardeas, the... Read more »
Kineta, Scouring the World for Cash, Finds Oil Money

Seattle-based Kineta has found some more support for its drug development work from an unlikely source—a group of oil traders.

The company said today it has raised an undisclosed amount of... Read more »
NanoString Technologies Maneuvers In Line for $86M IPO

NanoString Technologies just started selling its first diagnostic test after 10 years in business, and now it’s getting ready for another milestone—an initial public offering.

The Seattle-based company said today that... Read more »
Zillions of Biotech Conferences Want You. Which Should You Attend?

Biotech industry conferences are happening, somewhere on this green Earth, every day. If you’ve been around a while, and you’ve attended a few, chances are you get invitations, or marketing pitches,... Read more »

Page 1 of 169 next page »